Delayed Nasdaq  -  04:00 2022-08-17 pm EDT
40.87 USD   -2.78%
08/18WALGREENS BOOTS ALLIANCE, INC. : Ex-dividend day for
08/17SECTOR UPDATE : Health Care Stocks Set to Close Near Wednesday Lows
08/17MARKET CHATTER : Walgreens, Walmart, CVS Reportedly Told to Pay $650 Million Over Opioid Crisis Fallout in Ohio
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Biden presses companies on infant formula, FDA eyes more imports

05/12/2022 | 11:10am EDT
Empty shelves show a shortage of baby formula in San Antonio

(Adds context)

WASHINGTON, May 12 (Reuters) - U.S. President Joe Biden met on Thursday with executives from infant formula manufacturers and retailers including Target, Walmart and Nestle's Gerber, pressing them to do everything possible to get families access amid a nationwide shortage.

The White House also outlined measures the administration is taking to address the issue and said it was considering invoking the Defense Production Act.

The U.S. Food & Drug Administration (FDA) will announce new steps in the coming days regarding importing certain infant formula products from abroad, the White House said, and Biden has asked the Federal Trade Commission (FTC) to probe reports of predatory conduct such as price gouging.

Formula shortages because of a factory being taken offline have been compounded by supply chain snags and historic inflation, leaving about 40% of baby formula products out of stock nationwide, according to data firm Datasembly.

Families depend on formula. Less than half of babies born in the United States were exclusively breastfed through their first three months, the Centers for Disease Control and Prevention 2020 Breastfeeding Report Card showed.

During his meeting with the executives, Biden discussed efforts to increase production and urged companies to "do more to help families purchase infant formula," White House spokesperson Jen Psaki said.

"What we are seeing, which is an enormous problem, is hoarding," Psaki said. "That is also something we're focused on."

Biden later said on Twitter, "I'm announcing new actions and working with the private sector to get infant formula into stores as quickly as possible without compromising safety."

Tight supplies of formula dwindled further after Abbott Laboratories in February recalled Similac and other baby formula made at its Sturgis, Michigan, plant following consumer complaints of bacterial contamination. The FDA later cited five bacterial infections reported in babies given the company's formula, including two deaths.

Abbott, the biggest U.S. supplier of milk formula, said tests showed one bacteria strain found in the facility was not linked to any known infant illnesses, although it was updating its cleaning and related protocols.

Other major formula producers include Reckitt Benckiser and Nestle SA.

Several retailers, including Target Corp, CVS Health Corp and Walgreens Boots Alliance, have limited formula purchases until supplies improve to prevent hoarding. New York Attorney General Letitia James also has warned against price gouging.

U.S. House lawmakers plan a hearing on the matter on May 25.

House Speaker Nancy Pelosi told reporters lawmakers want to ensure it does not happen again, "but right now the baby's crying, the baby's hungry and we need to address the situation right now."

Last month, House Appropriations Committee Chairwoman Rosa DeLauro sought a Department of Health and Human Services probe, citing a whistleblower report from October 2021.

On Thursday, House Republicans criticized the Biden administration, saying a plan should have been in place to address the shortages sooner.

Abbott said it could restart production at Sturgis within two weeks of FDA approval, adding it is prioritizing production at its Columbus, Ohio, facility and air-shipping formula from its Ireland plant.

The company announced the recall on Feb. 17.

On Feb. 28, the FDA warned of Cronobacter sakazakii and Salmonella Newport infections in babies fed with formula produced at the Michigan plant. The FDA finished inspecting that facility on March 18, and the company responded on April 8, Abbott said. (Reporting by Jeff Mason, Susan Heavey and Trevor Hunnicutt in Washington, Jessica DiNapoli in New York and Leroy Leo in Bengaluru; Editing by Bill Berkrot, David Gregorio and Christian Schmollinger)

© Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
ABBOTT LABORATORIES -1.32% 110.55 Delayed Quote.-21.45%
CVS HEALTH CORPORATION -1.42% 104.92 Delayed Quote.1.71%
NESTLÉ S.A. 1.42% 116.86 Delayed Quote.-9.59%
RECKITT BENCKISER GROUP PLC 0.82% 6612 Delayed Quote.4.26%
S&P GSCI CLASS III MILK (USD) -0.86% 157.9347 Real-time Quote.1.25%
TARGET CORPORATION -2.69% 175.34 Delayed Quote.-24.24%
WALGREENS BOOTS ALLIANCE, INC. -2.78% 40.87 Delayed Quote.-21.64%
08/18WALGREENS BOOTS ALLIANCE, INC. : Ex-dividend day for
08/17SECTOR UPDATE : Health Care Stocks Set to Close Near Wednesday Lows
08/17MARKET CHATTER : Walgreens, Walmart, CVS Reportedly Told to Pay $650 Million Over Opioid C..
08/17SECTOR UPDATE : Health Care Stocks Trending Lower as Biotechs Fall
08/17SECTOR UPDATE : Health Care
08/17SECTOR UPDATE : Health Care Stocks Slip Premarket Wednesday
08/17Option Care Health Prices Secondary Offering by Walgreens Boots Alliance Affiliate at $..
08/16Walgreens Boots Alliance Sells 11 Million Shares of Option Care Health
08/16Option Care Health Says Walgreens Boots Alliance Affiliate Has Launched Secondary Offer..
08/15Flu Shots Are Now Available at Walgreens Nationwide for Everyone Aged 3 and Up
More news
Analyst Recommendations on WALGREENS BOOTS ALLIANCE, INC.
More recommendations
Financials (USD)
Sales 2022 132 B - -
Net income 2022 5 269 M - -
Net Debt 2022 9 403 M - -
P/E ratio 2022 6,72x
Yield 2022 4,71%
Capitalization 35 322 M 35 322 M -
EV / Sales 2022 0,34x
EV / Sales 2023 0,32x
Nbr of Employees 258 500
Free-Float 60,9%
Duration : Period :
Walgreens Boots Alliance, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends WALGREENS BOOTS ALLIANCE, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 19
Last Close Price 40,87 $
Average target price 42,83 $
Spread / Average Target 4,80%
EPS Revisions
Managers and Directors
Rosalind Gates Brewer Chief Executive Officer & Director
James Kehoe Global Chief Financial Officer & Executive VP
Stefano Pessina Executive Chairman
Francesco Tinto Global Chief Information Officer & Senior VP
Kevin M. Ban Chief Medical Officer
Sector and Competitors